Cibisatamab Biosimilar

Cibisatamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD3E/CEACAM5, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Cibisatamab (CEA-TCB) is a T cell bispecific antibody that binds carcinoembryonic antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab has a single CD3ε chain binding site and two CEA binding sites on T cells (it regulates the binding affinity to cancer cells with high expression of CEA on the cell surface). This avoids targeting healthy epithelial cells with low CEA expression levels. T cell activation, cytokine secretion and release of cytotoxic particles are triggered by binding to CEA on the surface of cancer cells and CD3 on T cells.

Target	CD3E/CEACAM5
Research Area	Humanized Monoclonal Antibodies, Biosimilars
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1 Kappa/lambda with domain crossover
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life	12 months.
Buffer	0.01 M PBS, pH 7.4.
CAS Number	2101242-53-7
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 5-10 working days.
Note	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Research Articles on CD3E/CEACAM5

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue